SERPINE1 and pancreatic neoplasm: Administering the anti-VEGF agent bevacizumab in this model promoted thrombosis by simultaneously increasing PAI-1 expression in tumours and in plasma, an effect that was reduced by a PAI-1 inhibitor.102 Further studies are needed to determine the role of hypofibrinolysis mediated by PAI-1 in pancreatic-cancer-associated thrombosis.